Shamburg News · 8-K filed Nov 16, 2026, 4:45 PM EST
iBio Reports Extended Preclinical IBIO-610 Obesity Data and Amylin Program Results
IBIO · iBio, Inc.
- Other event
- Reg FD disclosure
- Materiality: low
On November 16, 2026, iBio, Inc. furnished a press release highlighting 28-week preclinical data from a non-human primate study of IBIO-610, a long-acting Activin E-targeting antibody, presented at ObesityWeek 2026. The company reported a 2.3% reduction in body weight relative to vehicle at week 28 and 9.6% lower total fat at week 24, with lean mass generally maintained. The release also described preclinical amylin program data to be presented at PEGS Europe 2026 and the Amylin-Based Therapeutics Summit.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001104659-26-128453.
Written from the filing by Shamburg Markets. Figures are as reported by the company.